MX2018014278A - Microparticulas que comprenden un compuesto que contiene azufre. - Google Patents

Microparticulas que comprenden un compuesto que contiene azufre.

Info

Publication number
MX2018014278A
MX2018014278A MX2018014278A MX2018014278A MX2018014278A MX 2018014278 A MX2018014278 A MX 2018014278A MX 2018014278 A MX2018014278 A MX 2018014278A MX 2018014278 A MX2018014278 A MX 2018014278A MX 2018014278 A MX2018014278 A MX 2018014278A
Authority
MX
Mexico
Prior art keywords
microparticles
sulphur
containing compound
cysteamine
hydrate
Prior art date
Application number
MX2018014278A
Other languages
English (en)
Inventor
O'neil Deborah
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of MX2018014278A publication Critical patent/MX2018014278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

La presente invención proporciona macropartículas que comprenden un compuesto que contiene azufre, tal como cisteamina, o un éster, hidrato o sal farmacéuticamente aceptable de la misma. También se proporciona una composición que comprende las macropartículas y un agente estabilizador.
MX2018014278A 2016-06-07 2017-06-06 Microparticulas que comprenden un compuesto que contiene azufre. MX2018014278A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (1)

Publication Number Publication Date
MX2018014278A true MX2018014278A (es) 2019-03-14

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014278A MX2018014278A (es) 2016-06-07 2017-06-06 Microparticulas que comprenden un compuesto que contiene azufre.

Country Status (16)

Country Link
US (1) US11369568B2 (es)
EP (1) EP3463325B1 (es)
JP (1) JP7195934B2 (es)
KR (1) KR102412212B1 (es)
CN (1) CN109310654A (es)
AU (1) AU2017277897B2 (es)
BR (1) BR112018075221B1 (es)
CA (2) CA3096121C (es)
DK (1) DK3463325T3 (es)
ES (1) ES2965017T3 (es)
FI (1) FI3463325T3 (es)
GB (1) GB201609940D0 (es)
MX (1) MX2018014278A (es)
SG (1) SG11201810934TA (es)
WO (1) WO2017212249A1 (es)
ZA (1) ZA201807852B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
WO2020079186A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
EP4208153A1 (en) * 2020-09-03 2023-07-12 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) * 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
KR100770362B1 (ko) * 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
EA016795B1 (ru) 2006-12-22 2012-07-30 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Гель, применимый для доставки офтальмологических лекарственных средств
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
JP2012509922A (ja) * 2008-11-27 2012-04-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規粉末化結晶質吸入薬
JP5674684B2 (ja) 2009-02-03 2015-02-25 マイクロビオン コーポレーション 上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
EP2709646A4 (en) * 2011-05-19 2015-05-13 Savara Inc DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
MX2014004994A (es) * 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
WO2013120086A1 (en) * 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
CN106132403B (zh) * 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 喷雾干燥制剂
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Also Published As

Publication number Publication date
US11369568B2 (en) 2022-06-28
ZA201807852B (en) 2023-05-31
CA3026743A1 (en) 2017-12-14
AU2017277897A1 (en) 2018-12-20
JP2019517541A (ja) 2019-06-24
CN109310654A (zh) 2019-02-05
CA3096121A1 (en) 2017-12-14
ES2965017T3 (es) 2024-04-10
BR112018075221B1 (pt) 2024-02-06
GB201609940D0 (en) 2016-07-20
JP7195934B2 (ja) 2022-12-26
EP3463325A1 (en) 2019-04-10
BR112018075221A2 (pt) 2019-03-19
US20190175501A1 (en) 2019-06-13
WO2017212249A1 (en) 2017-12-14
KR102412212B1 (ko) 2022-06-23
AU2017277897B2 (en) 2022-09-08
KR20190016957A (ko) 2019-02-19
CA3096121C (en) 2022-11-15
EP3463325B1 (en) 2023-11-08
SG11201810934TA (en) 2019-01-30
FI3463325T3 (fi) 2023-12-19
DK3463325T3 (da) 2024-01-02
RU2018142841A (ru) 2020-06-04
RU2018142841A3 (es) 2020-09-30

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
MX2018014278A (es) Microparticulas que comprenden un compuesto que contiene azufre.
CR20200274A (es) Oxadiazoles fungicidas
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
WO2014144100A3 (en) Sgc stimulators
ZA201708234B (en) Delivery systems for controlled drug release
IL272055A (en) 8,1-naphthyridinone compounds and their uses
EP3698649A4 (en) MEANS TO PREVENT OR RELIEVE ALZHEIMER&#39;S MORBUS
EP3722395A4 (en) Anti-friction compound and anti-friction compound with the anti-friction compound
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2017008983A (es) Composición farmaceútica de sulfonamida.
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer&#39;s disease
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
SG11202003286YA (en) Cool-sensation imparter composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative
IL282999A (en) 4,3,1-oxadiazolone compound and drug
TW201613581A (en) Pharmaceutical composition for suppression of thromboembolization after stent placement
MY174415A (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof